In analogy to approaches targeting oncogenes encoding growth factors such as human epidermal growth factor receptor 2 (HER2) in breast cancer or protein kinases, e.g. BRAF in melanoma, oncogenic miRNAs as well might serve as therapeutic targets that could be silenced through application of antisense oligomers, called antagomiRs [19, 20]. The gene discussed is ERBB2; the disease is breast cancer.